Automated 3D-Body Composition Analysis as a Predictor of Survival in Patients With Idiopathic Pulmonary Fibrosis.
Journal
Journal of thoracic imaging
ISSN: 1536-0237
Titre abrégé: J Thorac Imaging
Pays: United States
ID NLM: 8606160
Informations de publication
Date de publication:
26 Aug 2024
26 Aug 2024
Historique:
medline:
26
8
2024
pubmed:
26
8
2024
entrez:
26
8
2024
Statut:
aheadofprint
Résumé
Idiopathic pulmonary fibrosis (IPF) is the most common interstitial lung disease, with a median survival time of 2 to 5 years. The focus of this study is to establish a novel imaging biomarker. In this study, 79 patients (19% female) with a median age of 70 years were studied retrospectively. Fully automated body composition analysis (BCA) features (bone, muscle, total adipose tissue, intermuscular, and intramuscular adipose tissue) were combined into Sarcopenia, Fat, and Myosteatosis indices and compared between patients with a survival of more or less than 2 years. In addition, we divided the cohort at the median (high=≥ median, low=<median) of the respective BCA index and tested the impact on the overall survival using the Kaplan-Meier methodology, a log-rank test, and adjusted multivariate Cox-regression analysis. A high Sarcopenia and Fat index and low Myosteatosis index were associated with longer median survival (35 vs. 16 mo for high vs. low Sarcopenia index, P=0.066; 44 vs. 14 mo for high vs. low Fat index, P<0.001; and 33 vs. 14 mo for low vs. high Myosteatosis index, P=0.0056) and better 5-year survival rates (34.0% vs. 23.6% for high vs. low Sarcopenia index; 47.3% vs. 9.2% for high vs. low Fat index; and 11.2% vs. 42.7% for high vs. low Myosteatosis index). Adjusted multivariate Cox regression showed a significant impact of the Fat (HR=0.71, P=0.01) and Myosteatosis (HR=1.12, P=0.005) on overall survival. The fully automated BCA provides biomarkers with a predictive value for the overall survival in patients with IPF.
Identifiants
pubmed: 39183570
doi: 10.1097/RTI.0000000000000803
pii: 00005382-990000000-00148
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Hutchinson J, Fogarty A, Hubbard R, et al. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J. 2015;46:795–806.
Hopkins RB, Burke N, Fell C, et al. Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada. Eur Respir J. 2016;48:187–195.
Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431–440.
Zheng Q, Cox IA, Campbell JA, et al. Mortality and survival in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. ERJ Open Res. 2022;8:00591–02021.
Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205:e18–e47.
Wiggins KJ, Johnson DW. The influence of obesity on the development and survival outcomes of chronic kidney disease. Adv Chronic Kidney Dis. 2005;12:49–55.
Gao M, Piernas C, Astbury NM, et al. Associations between body-mass index and COVID-19 severity in 6.9 million people in England: a prospective, community-based, cohort study. Lancet Diabetes Endocrinol. 2021;9:350–359.
Borga M, West J, Bell JD, et al. Advanced body composition assessment: from body mass index to body composition profiling. J Investig Med. 2018;66:1–9.
Hosch R, Kattner S, Berger MM, et al. Biomarkers extracted by fully automated body composition analysis from chest CT correlate with SARS-CoV-2 outcome severity. Sci Rep. 2022;12:16411.
Tolonen A, Pakarinen T, Sassi A, et al. Methodology, clinical applications, and future directions of body composition analysis using computed tomography (CT) images: a review. Eur J Radiol. 2021;145:109943.
Shirdel M, Andersson F, Myte R, et al. Body composition measured by computed tomography is associated with colorectal cancer survival, also in early-stage disease. Acta Oncol. 2020;59:799–808.
Catanese S, Aringhieri G, Vivaldi C, et al. Role of baseline computed-tomography-evaluated body composition in predicting outcome and toxicity from first-line therapy in advanced gastric cancer patients. J Clin Med. 2021;10:1079.
Kroll L, Mathew A, Baldini G, et al. CT-derived body composition analysis could possibly replace DXA and BIA to monitor NET-patients. Sci Rep. 2022;12:13419.
Caan BJ, Cespedes Feliciano EM, Prado CM, et al. Association of muscle and adiposity measured by computed tomography with survival in patients with nonmetastatic breast cancer. JAMA Oncol. 2018;4:798–804.
Alavi DH, Henriksen HB, Lauritzen PM, et al. Quantification of adipose tissues by dual-energy X-ray absorptiometry and computed tomography in colorectal cancer patients. Clin Nutr ESPEN. 2021;43:360–368.
Koitka S, Kroll L, Malamutmann E, et al. Fully automated body composition analysis in routine CT imaging using 3D semantic segmentation convolutional neural networks. Eur Radiol. 2021;31:1795–1804.
Alatzides GL, Haubold J, Steinberg HL, et al. Adipopenia in body composition analysis: a promising imaging biomarker and potential predictive factor for patients undergoing transjugular intrahepatic portosystemic shunt placement. Br J Radiol. 2023;96:20220863.
Beetz NL, Geisel D, Maier C, et al. Influence of baseline CT body composition parameters on survival in patients with pancreatic adenocarcinoma. J Clin Med. 2022;11:2356.
Alakhras M, Decker PA, Nadrous HF, et al. Body mass index and mortality in patients with idiopathic pulmonary fibrosis. CHEST. 2007;131:1448–1453.
Pugashetti J, Graham J, Boctor N, et al. Weight loss as a predictor of mortality in patients with interstitial lung disease. Eur Respir J. 2018;52:1801289.
Jalaber C, Lemerre-Poincloux J, Jouneau S, et al. Usefulness of body composition CT analysis in patients with idiopathic pulmonary fibrosis: a pilot study. Acad Radiol. 2022;29(suppl 2):S191–S201.
Moon SW, Choi JS, Lee SH, et al. Thoracic skeletal muscle quantification: low muscle mass is related with worse prognosis in idiopathic pulmonary fibrosis patients. Respir Res. 2019;20:35.
Awano N, Inomata M, Kuse N, et al. Quantitative computed tomography measures of skeletal muscle mass in patients with idiopathic pulmonary fibrosis according to a multidisciplinary discussion diagnosis: a retrospective nationwide study in Japan. Respir Investig. 2020;58:91–101.
Suzuki Y, Yoshimura K, Enomoto Y, et al. Distinct profile and prognostic impact of body composition changes in idiopathic pulmonary fibrosis and idiopathic pleuroparenchymal fibroelastosis. Sci Rep. 2018;8:14074.
Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e44–e68.
Bachettini NP, Bielemann RM, Barbosa-Silva TG, et al. Sarcopenia as a mortality predictor in community-dwelling older adults: a comparison of the diagnostic criteria of the European Working Group on Sarcopenia in Older People. Eur J Clin Nutr. 2020;74:573–580.
Chuang S-Y, Chang H-Y, Lee M-S, et al. Skeletal muscle mass and risk of death in an elderly population. Nutr Metab Cardiovasc Dis. 2014;24:784–791.
Buentzel J, Heinz J, Bleckmann A, et al. Sarcopenia as prognostic factor in lung cancer patients: a systematic review and meta-analysis. Anticancer Res. 2019;39:4603–4612.
Tuttle LJ, Sinacore DR, Mueller MJ. Intermuscular adipose tissue is muscle specific and associated with poor functional performance. J Aging Res. 2012;2012:172957.
Miljkovic I, Kuipers AL, Cauley JA, et al. Greater skeletal muscle fat infiltration is associated with higher all-cause and cardiovascular mortality in older men. J Gerontol A Biol Sci Med Sci. 2015;70:1133–1140.
McDonald M-LN, Wouters EFM, Rutten E, et al. It’s more than low BMI: prevalence of cachexia and associated mortality in COPD. Respir Res. 2019;20:100.
Lee JK, Chung C, Kim J, et al. Clinical impact of weight loss on mortality in patients with idiopathic pulmonary fibrosis: a retrospective cohort study. Sci Rep. 2023;13:5774.
Nakatsuka Y, Handa T, Kokosi M, et al. The clinical significance of body weight loss in idiopathic pulmonary fibrosis patients. Respiration. 2018;96:338–347.
Nishiyama O, Yamazaki R, Sano H, et al. Fat-free mass index predicts survival in patients with idiopathic pulmonary fibrosis. Respirology. 2017;22:480–485.
Bernardinello N, Petrarulo S, Grisostomi G, et al. Loss of muscle mass in idiopathic pulmonary fibrosis. Eur Respir J. 2022;60:3406.
Patel S, Nolan C, Barker R, et al. Body composition and mortality in idiopathic pulmonary fibrosis (IPF): a prospective cohort study. Eur Respir J. 2018;52(suppl 62). doi:10.1183/13993003.congress-2018.PA2056
doi: 10.1183/13993003.congress-2018.PA2056
Zinellu A, Carru C, Pirina P, et al. A systematic review of the prognostic significance of the body mass index in idiopathic pulmonary fibrosis. J Clin Med. 2023;12:498.
Abramowitz MK, Hall CB, Amodu A, et al. Muscle mass, BMI, and mortality among adults in the United States: a population-based cohort study. PLoS One. 2018;13:e0194697.
Deurenberg P, Deurenberg-Yap M, Guricci S. Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship. Obes Rev. 2002;3:141–146.
NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet. 2016;387:1377–1396.
Jouneau S, Crestani B, Thibault R, et al. Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis. Respir Res. 2020;21:312.
Nachit M, Horsmans Y, Summers RM, et al. AI-based CT body composition identifies myosteatosis as key mortality predictor in asymptomatic adults. Radiology. 2023;307:e222008.